Company Overview and News

 
Cobalt 27: Don't Forget The Nickel Exposure

2018-09-19 seekingalpha
This article was first published on Trend Investing on September 13; therefore, all data is as of that date.
CLA FT PSDNF AYR CCZ HAV AEOMF CZI KATFF POS HIG AUZ RNX KAT FTMDF GME CNJ HLPCF CSSQF AQR

15
Cobalt Miners News For The Month Of August 2018

2018-08-23 seekingalpha
Cobalt miner news - BHP seeking to add cobalt sulphate from Nickel West operation. China Molybdenum net profit set to surge between 271.21% and 295.16%.
SIE PIO CLA PANRF BLT CCZ PAN HAV MCR KBGCF CTM AXE ECSIF IGO VIC BAR AOU HIG PCRCF PLM.RT SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR CDU RGARF CHK MCRZY FTMDF KAT RER BBL CSSQF BHPLF GMRSF CZN PGM GBLEF NZRIF AZS GLCNF DLE HBNRF MEI PIONF GAL CZI AMSLF BPLNF HMI POS AUZ RNX GME FQVLF AQR PTNUF FT BHPBF HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF FTSSF KATFF BBBMF MLXEF OZMLF PLM BHP CNJ AZRMF HLPCF BPL BHP OZL ARV

 
Africa Down Under Conference Perth to highlight mining and energy investments

2018-08-22 proactiveinvestors.com.au
Africa Down Under Conference Perth kicks off next Wednesday as mines ministers, government delegates and leaders of key Australian companies operating in Africa converge amid the mining sector’s resurgence.
CLA BSSMF IGO S32 AZM BSRUF CDNL RSG BSE BKT LOM RMGGF ILKAY BSM SOUHY ILKAF IIDDY ILU CDV BSE ORN SRI RMGGY AZUMF SHTLF

17
Cobalt Miners News For The Month Of July 2018

2018-07-23 seekingalpha
Cobalt market news - Darton forecasts 40% growth in cobalt demand in 2018. Tony Southgate (ERG) says: "The cobalt boom is guaranteed for the next seven to 10 years."
SIE PIO CLA PANRF RIO CCZ PAN HAV MCR KBGCF CTM FCX AXE IGO VIC BAR AOU HIG PCRCF PLM.RT SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR SHERF CDU RGARF CHK MCRZY CLQ FTMDF KAT RIO RER CSSQF GMRSF CZN PGM GBLEF NZRIF RIO AZS GLCNF DLE HBNRF MEI PIONF CZI AMSLF BPLNF HMI POS AUZ RNX RTPPF GME RTNTF FQVLF AQR PTNUF FT HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF FTSSF KATFF BBBMF MLXEF OZMLF PLM CNJ AZRMF HLPCF BPL BHP OZL ARV

 
Celsius Resources begins airborne survey at Namibian cobalt project

2018-07-19 proactiveinvestors.com.au
Celsius Resources Ltd (ASX:CLA) has begun an airborne electromagnetic survey at its Opuwo Cobalt Project in Namibia.
CLA

8
Top 6 Cobalt Junior Developer Miners To Boom By 2021/2022

2018-05-17 seekingalpha - 1
Six cobalt junior developers can each produce ~5,000 tonnes pa of cobalt by 2021/22. These companies each have the potential to be worth ~AUD 3b if cobalt prices remain strong.
CLA CCZ HAV GLCNF ECSIF CZI AMSLF BPLNF POS HIG AUZ RNX RNKLF GME AQR FT PSDNF AYR AEOMF KATFF RNX.WT FTMDF KAT CNJ BPL HLPCF CSSQF

1
Celsius Resources attracts $9 million to progress cobalt project in Namibia

2018-05-03 proactiveinvestors.com.au - 1
Celsius Resources Ltd’s (ASX:CLA) shares closed 7.5% higher at 22 cents after completing a bookbuild to raise $9 million via the issue of shares at 18.5 cents each to institutional and professional investors. The funds raised from the North American, Hong Kong, European and Australian investors will be applied primarily to fund the progression of the Opuwo Cobalt Project in Namibia.
CLA

 
Cazaly Resources extends cobalt prospective land position in Namibia

2018-05-03 proactiveinvestors.com.au
Cazaly Resources Limited (ASX:CAZ) has completed the acquisition of the Kaoko Kobalt project in the Kunene Cobalt Province, northern Namibia.
CLA CAZ

 
Celsius Resources shares rise on maiden cobalt resource in Namibia

2018-04-16 proactiveinvestors.com.au
Celsius Resources Ltd’s (ASX:CLA) shares are trading about 22% higher intra-day at 20 cents after revealing a maiden cobalt resource at its 95% owned Opuwo Cobalt Project in Namibia.
CLA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:CLA / CELSIUS COAL LIMITED on message board site Silicon Investor.

Classic TA Workplace Classic TA Workplace Classic TA Workplace Berkshire Hathaway Class B Berkshire Hathaway Class B Berkshire Hathaway Class B
Oclaro, Inc. (Avanex-Bookham) Oclaro, Inc. (Avanex-Bookham) Oclaro, Inc. (Avanex-Bookham) Clayton Williams Energy (CWEI) OIL Clayton Williams Energy (CWEI) OIL Clayton Williams Energy (CWEI) OIL
For the Sake of Clarity and Meaning For the Sake of Clarity and Meaning For the Sake of Clarity and Meaning Empire Capital agreement for 30 Newfoundland claims Empire Capital agreement for 30 Newfoundland claims Empire Capital agreement for 30 Newfoundland claims
Hecla Mining(HL) Hecla Mining(HL) Hecla Mining(HL) 2 CLAPS THEN LUBRICATE, PICTURES ONLY 2 CLAPS THEN LUBRICATE, PICTURES ONLY 2 CLAPS THEN LUBRICATE, PICTURES ONLY
NTG - Clarity Networks NTG - Clarity Networks NTG - Clarity Networks Kathleen Willey blasts Hillaryu0027s u0027dead brokeu0027 claim Kathleen Willey blasts Hillaryu0027s u0027dead brokeu0027 claim Kathleen Willey blasts Hillaryu0027s u0027dead brokeu0027 claim